Fusion Pharmaceuticals (FUSN) News Today → A.I. is a Tidal Wave - Here’s What to Buy (From Chaikin Analytics) (Ad) Free FUSN Stock Alerts $21.48 +0.10 (+0.47%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Given Average Rating of "Hold" by Brokeragesamericanbankingnews.com - May 10 at 2:54 AMWilliam Blair Weighs in on Fusion Pharmaceuticals Inc.'s Q2 2024 Earnings (NASDAQ:FUSN)americanbankingnews.com - May 10 at 2:16 AMFusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancerprnewswire.com - May 9 at 4:14 PMFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSNbusinesswire.com - May 9 at 3:34 PMQ2 2024 EPS Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Boosted by William Blairmarketbeat.com - May 9 at 6:52 AMFUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q1 2024investorplace.com - May 7 at 3:22 PMFusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updatesprnewswire.com - May 7 at 7:00 AMFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Sees Significant Drop in Short Interestmarketbeat.com - May 1 at 6:53 PMFusion Pharmaceuticals (NASDAQ:FUSN) Hits New 12-Month High at $21.56marketbeat.com - May 1 at 4:49 PMJennison Associates LLC Makes New Investment in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)marketbeat.com - April 27 at 6:08 AMTop 4 Health Care Stocks That May Plunge This Monthmsn.com - April 26 at 10:55 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Laboratory (LH), Fusion Pharmaceuticals (FUSN) and Integer Holdings (ITGR)markets.businessinsider.com - April 26 at 10:55 AMFusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Orderprnewswire.com - April 25 at 4:34 PMFusion Pharmaceuticals Inc Ordinary Sharesmorningstar.com - April 19 at 10:41 PMFederated Hermes Inc. Acquires 202,364 Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)marketbeat.com - April 19 at 8:27 AMFusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should Knowfinance.yahoo.com - April 17 at 11:59 PMTD Cowen Downgrades Fusion Pharmaceuticals (FUSN)msn.com - April 17 at 8:57 AMHealthInvest Partners AB Makes New Investment in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)marketbeat.com - April 16 at 6:50 PMFusion Pharmaceuticals (NASDAQ:FUSN) Earns "Hold" Rating from TD Cowenmarketbeat.com - April 16 at 8:19 AMLeerink Partnrs Analysts Cut Earnings Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)marketbeat.com - April 12 at 6:08 AMFusion Pharmaceuticals Inc. (NASDAQ:FUSN) is definitely on the radar of institutional investors who own 46% of the companyfinance.yahoo.com - April 11 at 7:12 PMFusion Pharmaceuticals (NASDAQ:FUSN) Sees Large Volume Increasemarketbeat.com - April 11 at 2:49 PMFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024finance.yahoo.com - April 9 at 7:24 PMFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024prnewswire.com - April 9 at 4:05 PMFusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 12-Month High at $21.55marketbeat.com - April 4 at 6:52 PMGenmab Buys ProfoundBio for $1.8B to Boost Oncology Portfoliomsn.com - April 3 at 9:15 AMFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Short Interest Down 8.3% in Marchmarketbeat.com - April 2 at 4:51 PMWhat Fusion Pharmaceuticals (NASDAQ:FUSN) Acquisition Means for Investorsmsn.com - March 28 at 8:54 PMINVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSNprnewswire.com - March 26 at 7:48 PMFusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 1-Year High at $21.32marketbeat.com - March 25 at 11:17 AMYarbrough Capital LLC Acquires Shares of 76,872 Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)marketbeat.com - March 24 at 10:40 AMFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Expected to Earn FY2023 Earnings of ($1.36) Per Sharemarketbeat.com - March 22 at 7:34 AMFY2026 EPS Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Raised by Analystmarketbeat.com - March 21 at 8:36 AMFusion Pharmaceuticals (NASDAQ:FUSN) Downgraded by Bloom Burtonmarketbeat.com - March 21 at 7:57 AMFUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023msn.com - March 20 at 10:26 PMFusion Pharmaceuticals: Hold Rating Justified Amid Acquisition and Radiopharmaceutical Market Dynamicsmarkets.businessinsider.com - March 20 at 5:21 PMKuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law Firmstockhouse.com - March 20 at 5:21 PMFusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updatesfinance.yahoo.com - March 20 at 5:21 PMUnveiling 11 Analyst Insights On Fusion Pharmaceuticalsmarkets.businessinsider.com - March 20 at 12:21 PMB. Riley Reiterates "Neutral" Rating for Fusion Pharmaceuticals (NASDAQ:FUSN)marketbeat.com - March 20 at 10:39 AMFusion Pharmaceuticals (NASDAQ:FUSN) Downgraded to "Market Perform" at Leerink Partnrsmarketbeat.com - March 20 at 5:42 AMFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSNbusinesswire.com - March 19 at 11:05 PMFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSNbusinesswire.com - March 19 at 9:01 PMTraders Purchase High Volume of Put Options on Fusion Pharmaceuticals (NASDAQ:FUSN)marketbeat.com - March 19 at 3:53 PMFusion Pharmaceuticals' (FUSN) Hold Rating Reiterated at Truist Financialmarketbeat.com - March 19 at 12:41 PMHeard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Dealfinance.yahoo.com - March 19 at 11:24 AMSuper Micro, XPeng, AstraZeneca: Trending tickersfinance.yahoo.com - March 19 at 11:24 AMFusion Rockets 97%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeoverfinance.yahoo.com - March 19 at 11:24 AMFusion Pharmaceuticals (NASDAQ:FUSN) Hits New 1-Year High at $21.12marketbeat.com - March 19 at 11:14 AMAstraZeneca to buy Canadian cancer treatment developer Fusion Pharmaceuticalsfinancialpost.com - March 19 at 10:07 AM Get Fusion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter. Email Address The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about... Click here to see Louis' new video for yourself. FUSN Media Mentions By Week FUSN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FUSN News Sentiment▼0.230.55▲Average Medical News Sentiment FUSN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FUSN Articles This Week▼133▲FUSN Articles Average Week Get Fusion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Inhibrx News Beam Therapeutics News Ginkgo Bioworks News ADMA Biologics News Recursion Pharmaceuticals News Neumora Therapeutics News Tarsus Pharmaceuticals News Sana Biotechnology News Apogee Therapeutics News 4D Molecular Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FUSN) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeCollapse of the Petrodollar Colonial MetalsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
